
Exosome Communication
Advances in Research and Therapeutics for Health and Disease
- 1st Edition - November 15, 2024
- Imprint: Academic Press
- Authors: Dalapathi Gugulothu, Dharmendra Kumar Khatri, Lalitkumar K. Vora, William C.S. Cho
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 9 0 5 2 - 7
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 9 0 5 3 - 4
Exosome Communication: Advances in Research and Therapeutics for Health and Disease serves as a crucial reference for pharmaceutical scientists, focusing on the key qualit… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quote- Comprehensive Coverage: Detailed exploration of the research history, development, and different isolation techniques of exosomes.
- Therapeutic Applications: In-depth discussion of the diverse therapeutic applications of exosomes in health and disease.
- Development Challenges: Insightful analysis of the challenges for the development of exosome nanovesicle-based formulations for drug delivery.
- Title of Book
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter 1. Introduction: History and development of exosomes nanovesicles
- 1.1 Introduction
- 1.1.1 Early observation and historical context
- 1.1.2 Evolution of EXO terminology and nomenclature
- 1.1.3 Pioneering studies in EXO research
- 1.1.4 Milestones in EXO NV research
- 1.1.5 Emerging paradigms and future direction
- 1.2 Conclusion
- Chapter 2. Exploring extracellular vesicles: Understanding exosomes and beyond
- 2.1 Introduction
- 2.2 Biogenesis and composition of exosomes
- 2.2.1 Cellular pathways involved in exosomes biogenesis
- 2.2.1.1 Endosomal sorting complex required for transport (ESCRT) pathway
- 2.2.1.2 ESCRT independent pathways
- 2.2.2 Composition of exosomes
- 2.2.2.1 Proteins
- 2.2.2.2 Nucleic acids
- 2.2.2.3 Lipids
- 2.2.2.4 Carbohydrates
- 2.3 Function of exosomes in cellular communication
- 2.3.1 Intercellular communication
- 2.3.2 Immune regulation
- 2.3.3 Waste management and cellular remodeling
- 2.3.4 Angiogenesis and vascular homeostasis
- 2.4 Beyond exosomes—Microvesicles and apoptotic bodies
- 2.4.1 Microvesicles
- 2.4.2 Apoptotic bodies
- 2.5 Profiling extracellular vesicles cargo: Insights into molecular signatures
- 2.5.1 Methodologies for cargo profiling
- 2.5.1.1 Proteomics
- 2.5.1.2 Genomics and transcriptomics
- 2.5.1.3 Lipidomics
- 2.5.2 Molecular signatures of exosomes
- 2.5.2.1 Surface markers
- 2.5.2.2 Cargoes reflecting cellular state
- 2.5.2.3 Functional proteins
- 2.6 Extracellular vesicles as diagnostic and therapeutic tools: Breakthroughs and challenges
- 2.6.1 Diagnostic applications
- 2.6.1.1 Biomarker discovery
- 2.6.1.2 Liquid biopsies
- 2.6.2 Therapeutic potentials
- 2.6.2.1 Drug delivery vehicles
- 2.6.2.2 Regenerative medicine
- 2.6.3 Breakthroughs
- 2.6.3.1 Precision medicine
- 2.6.4 Challenges
- 2.7 Future directions and conclusion
- Chapter 3. Exosome isolation techniques: Methods, protocols, and best practices
- 3.1 Introduction to exosomes isolation
- 3.1.1 Discovery and definition
- 3.1.2 Structure and composition
- 3.1.3 Types of exosomes
- 3.1.4 Exosomes biogenesis
- 3.1.5 Exosome release
- 3.1.6 Exosome uptake
- 3.2 Isolation of exosomes from biological materials
- 3.2.1 Isolation from cell culture
- 3.2.2 EVS extraction from blood
- 3.2.3 EVS separation from tissue
- 3.3 Exosome extraction methodologies
- 3.3.1 Ultracentrifugation
- 3.3.1.1 Differential ultracentrifugation
- 3.3.1.2 Density gradient ultracentrifugation (DGUC)
- 3.3.2 Precipitation
- 3.3.3 Size based technique
- 3.3.3.1 Ultrafiltration
- 3.3.3.2 Size exclusion chromatography (SEC)
- 3.3.4 Affinity capture with biopolymers
- 3.3.5 Molecular Imprinted Polymers (MIP)
- 3.3.6 Microfluidic technologies for exosome isolation
- 3.3.6.1 Immunological separation
- 3.3.6.2 Trapping on porous structures
- 3.3.6.3 Sieving
- 3.4 Challenges of separation methods
- 3.5 Summary and conclusion
- Chapter 4. Improving cargo loading and release strategies for exosomes nanovesicles
- 4.1 Introduction
- 4.2 Role of EXOs in targeted drug delivery
- 4.2.1 Role of EXOs in tumor development
- 4.2.2 Role of EXOs in disease diagnosis
- 4.2.3 Role of EXOs for wound healing
- 4.2.4 Advantages of EXOs as drug carriers
- 4.3 Various strategies for cargo loading into EXOs
- 4.3.1 Incubation
- 4.3.2 Cell transfection
- 4.3.3 Physical treatments
- 4.3.3.1 Electroporation
- 4.3.3.2 Sonication
- 4.3.3.3 Freeze thaw method
- 4.3.3.4 Extrusion
- 4.3.4 Surfactant treatment
- 4.3.5 Dialysis
- 4.4 In situ assembly and synthesis
- 4.5 Emerging paradigms in cargo loading
- 4.5.1 EXOs derived from tumor cells
- 4.5.2 Bronchial fibroblast-derived EXOs
- 4.5.3 Osteoclast-derived EXOs
- 4.5.4 Rhabdomyosarcoma (RMS) derived EXOs
- 4.5.5 Milk-derived EXOs
- 4.6 Conclusion
- Chapter 5. Exosome characterization techniques, composition analysis and contents of exosomes nanovesicles: Methods and interpretation
- 5.1 Introduction
- 5.2 Morphological characterization techniques: EM and AFM
- 5.3 Molecular analysis of EXO composition
- 5.4 Advanced technologies in EXO characterization
- 5.5 Data interpretation and insights
- 5.6 Future directions and emerging techniques in EXO characterization
- 5.7 Conclusion
- Chapter 6. Quality control, minimizing heterogeneity and enhancing yield in exosome isolation and production
- 6.1 Introduction
- 6.1.1 Quality control in exosome isolation
- 6.1.1.1 Quantification methods
- 6.1.1.2 Morphology assessment
- 6.1.2 Minimizing heterogeneity in exosome isolation
- 6.1.2.1 Biogenesis of exosome populations and subpopulations
- 6.1.2.2 Stochasticity
- 6.1.3 Enhancing yield in exosome production
- 6.1.3.1 Selection of stem cells
- 6.1.3.2 Culture methods of stem cells
- 6.1.3.3 Isolation of exosomes
- 6.1.3.4 Artificial exosomes
- 6.1.4 Standardized protocols for large-scale production
- 6.1.5 Quality control measures for exosome characterization
- 6.1.5.1 Importance of quality control in exosome studies
- 6.1.5.2 Criteria for exosome quality assessment
- 6.1.5.3 Quantitative, qualitative, and single vesicle characterization methods
- 6.1.6 Practical approaches and best practices
- 6.1.6.1 As delivery system for therapeutic applications
- 6.1.6.2 Loading approaches
- 6.1.6.3 Disease diagnosis
- 6.1.6.4 Exosome modification for targeted delivery to specific tissues or cells
- 6.2 Conclusion and future Directions
- Chapter 7. Inhibition of cell-cell communication in exosomes
- 7.1 Introduction
- 7.2 Mechanisms of exosome-mediated communication
- 7.2.1 Exosome biogenesis and release
- 7.2.2 Cargo loading and content diversity in exosomes
- 7.2.3 Uptake mechanisms by recipient cells
- 7.3 Targeting exosome biogenesis inhibition
- 7.3.1 Inhibitors of exosome biogenesis pathways
- 7.3.1.1 Exosome release by calcium (Ca2+) regulation
- 7.3.1.2 Exosome release by cellular acidification
- 7.3.1.3 Exosome inhibitors targeting Ras-related protein (RAB27A)
- 7.3.1.4 Small molecules affecting lipid metabolism
- 7.3.1.5 Others
- 7.3.2 Disrupting exosome uptake
- 7.3.2.1 Inhibitors of receptor-mediated endocytosis
- 7.3.3 Therapeutic applications of exosome inhibitors
- 7.4 Conclusion
- Chapter 8. Bioengineering and modification of exosome nanovesicles for targeted drug delivery
- 8.1 Introduction
- 8.2 Understanding and leveraging exosomes
- 8.2.1 Biogenesis
- 8.2.2 Compositions and biological functions
- 8.2.3 Isolation techniques
- 8.2.4 Loading approaches for therapeutic cargo
- 8.3 Need for bioengineering strategies
- 8.4 Bioengineering strategies for targeted delivery
- 8.4.1 Genetic engineering
- 8.4.2 Chemical modification
- 8.4.3 Exosome-nanoparticle hybrids
- 8.5 State-of-the-art examples
- 8.5.1 Cancer therapy
- 8.5.2 Inflammation and autoimmune disorders
- 8.5.3 Regenerative medicine
- 8.6 Challenges and potential solutions
- 8.7 Concluding remark
- Chapter 9. Challenges in exosome nanovesicle-based drug delivery and diagnostics
- 9.1 Introduction and background
- 9.2 Exosomes in drug delivery
- 9.3 Exosomes in disease diagnosis
- 9.4 Challenges in clinical application
- 9.4.1 For drug delivery
- 9.4.1.1 Biological variability
- 9.4.1.2 Scalability and manufacturing
- 9.4.1.3 Storage and stability
- 9.4.1.4 Regulatory and safety issues
- 9.4.2 For disease diagnosis
- 9.4.2.1 Sensitivity and specificity
- 9.4.2.2 Standardization of the diagnostic protocol
- 9.4.2.3 Technological/instrumentation limitations
- 9.4.2.4 Economic barriers
- 9.5 Future prospects and concluding remarks
- Chapter 10. Diagnostic potential and biomarkers potential of exosome nanovesicles
- 10.1 Introduction
- 10.2 Exosome characteristics: Favorable features as biomarkers
- 10.2.1 Physical and surface characteristics of exosomes
- 10.2.2 Biomarker potential of exosomes
- 10.2.3 Exosome nanovesicles as diagnostic carriers
- 10.2.4 Advantages of exosomes as diagnostic aids
- 10.3 Exosomes in disease diagnosis
- 10.3.1 Isolation of exosomes
- 10.3.2 Exosome characterization
- 10.3.3 Biochemical analysis of exosomal cargo
- 10.4 Diagnostic and biomarker potential of exosomes in cancer
- 10.4.1 In leukemias
- 10.4.2 In lung cancer
- 10.4.3 In breast cancer
- 10.4.4 In other cancers
- 10.5 Diagnostic and biomarker potential of exosomes in neurodegenerative disorders
- 10.5.1 CNS- cell specific markers
- 10.5.2 In Alzheimer's disease
- 10.5.3 In Parkinson's disease (PD)
- 10.5.4 Exosomes in other NDDS
- 10.6 Diagnostic and biomarker potential of exosomes in immune disorders
- 10.7 Diagnostic and biomarker potential of exosomes in other diseases
- 10.7.1 In cardiovascular diseases
- 10.7.2 In liver diseases
- 10.8 Challenges and way forward
- Chapter 11. Immunological exosomes: An upcoming cue for disease management
- 11.1 Introduction
- 11.2 Exosome's biogenesis and distribution
- 11.3 Exosomes and immune system
- 11.3.1 Innate immune response
- 11.3.2 Adaptive immune response
- 11.4 Exosomes in pathology
- 11.4.1 Cancer
- 11.4.2 Joint and bone diseases
- 11.4.3 Dental diseases
- 11.4.4 Ophthalmic disease
- 11.4.5 Neurological disease
- 11.4.6 Cardiovascular complications
- 11.4.7 Reproductive diseases
- 11.5 Prognostic avenue of exosomes
- 11.6 Recent advancement and challenges of exosome-based disease management
- 11.7 Conclusion
- Chapter 12. Exosomes for protein and peptide drug delivery
- 12.1 Introduction
- 12.1.1 Biogenesis of exosomes
- 12.1.2 Separation and purification of exosomes
- 12.1.3 Drug loading
- 12.1.4 Hybrid method for loading
- 12.2 Exosomes for peptide delivery
- 12.2.1 Ophthalmic delivery
- 12.2.2 Cardiac delivery
- 12.2.3 Osteoarthritis
- 12.2.4 Spinal cord injury
- 12.2.5 Hepatic delivery
- 12.2.6 Central nervous system
- 12.2.7 Immunotherapy
- 12.2.8 Cancer
- 12.3 Applications of exosomes-based protein delivery
- 12.3.1 Hepatic delivery
- 12.3.2 Lymphatic delivery
- 12.3.3 CNS delivery
- 12.3.4 Anticancer therapy
- 12.3.5 Muscular dystrophy
- 12.3.6 Biomedical application
- 12.3.7 Immunization
- 12.3.8 CNS disorders
- 12.3.9 Miscellaneous
- 12.4 Conclusion and future perspective
- Chapter 13. Exosomes nanovesicles for gene delivery and vaccination
- 13.1 Introduction
- 13.2 Exosome as nanocarrier
- 13.2.1 Background and brief overview
- 13.2.2 Key characteristics
- 13.2.2.1 Cellular targeting and tissue tropism
- 13.2.2.2 Stability and immunogenicity
- 13.2.2.3 Biodegradability and clearance
- 13.2.3 Engineering for enhanced delivery
- 13.2.3.1 Loading of therapeutic payload
- 13.2.3.2 Modifications for targeting
- 13.3 Exosomes for gene delivery
- 13.3.1 Advantages over conventional vectors
- 13.3.2 Exosome-mediated delivery of mRNA
- 13.3.3 Exosome-mediated delivery of siRNA/miRNA
- 13.3.4 Exosome-mediated delivery of CRISPR-Cas9
- 13.4 Exosomes for vaccination
- 13.4.1 Interaction with immune system
- 13.4.2 Inherent immunomodulatory properties
- 13.4.3 Exosome-based immunization strategies
- 13.4.3.1 Therapeutic cancer vaccines
- 13.4.3.2 Viral infectious diseases
- 13.4.3.3 Non-viral infectious diseases
- 13.5 Clinical status
- 13.6 Challenges and future prospects
- 13.7 Conclusions
- Chapter 14. Theranostic potential of exosomes in neurodegenerative diseases
- 14.1 Introduction
- 14.1.1 Biogenesis of brain exosomes
- 14.1.2 Uptake of brain exosomes
- 14.1.3 Isolation of brain exosomes
- 14.1.4 Brain exosome composition
- 14.1.5 Characteristics of exosomes
- 14.2 Physiological role of exosomes in neurodegenerative diseases
- 14.2.1 Exosomes in Alzheimer's disease
- 14.2.2 Exosomes in Parkinson's disease
- 14.2.3 Exosomes in Huntington's disease (HD)
- 14.2.4 Exosomes in amyotrophic lateral sclerosis (ALS)
- 14.3 Therapeutic roles of exosomes in neurodegenerative diseases
- 14.3.1 Exosomes and Alzheimer's disease
- 14.3.2 Exosomes and Parkinson disease
- 14.3.3 Exosomes and Huntington disease
- 14.3.4 Exosomes and amyotrophic lateral sclerosis (ALS)
- 14.4 Exosome in diagnosis of neurodegenerative diseases
- 14.4.1 Exosomes as potential biomarker
- 14.5 Exosomes application in drug delivery and vaccine
- 14.5.1 Drug delivery
- 14.5.2 Vaccination
- 14.6 Conclusion and perspective
- Chapter 15. Exosomes in cancer therapeutic delivery
- 15.1 Introduction
- 15.1.1 Carcinoma
- 15.1.2 Sarcoma
- 15.1.3 Leukemia
- 15.1.4 Melanoma
- 15.1.5 Lymphoma
- 15.2 Role of exosomes in diagnosis and treatment of cancer
- 15.3 Exosomes in different types of cancer
- 15.3.1 Exosomes in breast cancer
- 15.3.2 Exosomes in lung cancer
- 15.3.3 Exosomes in colorectal cancer
- 15.3.4 Exosomes in prostate cancer
- 15.3.5 Exosomes in ovarian cancer
- 15.3.6 Exosomes in brain cancer
- 15.3.7 Exosomes in oral cancer
- 15.3.8 Exosomes in hepatic cancer
- 15.3.9 Exosomes in leukemia
- 15.4 Conclusion
- Chapter 16. Potential role of parasite-derived exosomes in human diseases
- 16.1 Introduction
- 16.2 EVs and parasitic protozoa
- 16.2.1 Malaria
- 16.2.1.1 The life cycle of Plasmodium
- 16.2.1.2 The role of EVs in malaria
- 16.2.2 Visceral leishmaniasis
- 16.2.3 Trypanosomiasis
- 16.2.4 Toxoplasmosis
- 16.3 The therapeutic potential of EVs in parasitic diseases
- 16.4 Conclusion
- Chapter 17. Current applications of new generations of exosomes nanovesicles
- 17.1 Introduction
- 17.2 Methods for EXOs engineering
- 17.2.1 Loading EXOs with therapeutic cargo
- 17.2.2 Surface modification of EXOs
- 17.2.3 Isolation and purification techniques
- 17.2.4 Microfluidics and nanotechnology
- 17.2.5 Quality control and characterization
- 17.3 EXOs in cardiovascular diseases: Cardioprotection and vascular health
- 17.3.1 EXOs and cardio protection
- 17.3.2 EXOs in vascular health
- 17.4 EXOs in regenerative medicine: Tissue engineering and wound healing
- 17.4.1 Tissue engineering
- 17.4.2 Wound healing
- 17.5 Emerging trends and future perspective
- 17.5.1 Diagnostic biomarkers
- 17.5.2 Therapeutic applications
- 17.5.3 Precision medicine
- 17.5.4 Neurodegenerative diseases
- 17.5.5 Immunomodulation
- 17.5.6 Standardization in isolation and characterization
- 17.5.7 EXO engineering advancements
- 17.5.8 Clinical translation
- 17.5.9 Biomimetic nanotechnology
- 17.6 Conclusion
- Chapter 18. Clinical trials and translational research in exosome nanovesicle therapeutics
- 18.1 Introduction
- 18.2 Exosome nanovesicle
- 18.2.1 Structural characteristics and exosome biogenesis
- 18.2.2 Biological functions and diagnostic markers and therapeutics delivery vehicle
- 18.3 Translational research—Exosome therapeutics
- 18.3.1 Preclinical studies-exosome therapeutics
- 18.3.1.1 Cancer studies
- 18.3.1.2 Neurological diseases
- 18.3.1.3 Immunological disease
- 18.3.1.4 Others
- 18.3.2 Clinical trials-exosome therapeutics
- 18.3.2.1 Cancer studies
- 18.3.2.2 Neurological and psychiatric diseases
- 18.3.2.3 Immunological diseases
- 18.3.2.4 Others
- 18.4 Translational findings into clinical practice and future directions
- 18.5 Conclusion
- Chapter 19. Scale-up and manufacturing of exosome-based therapeutics
- 19.1 Introduction
- 19.2 Need for exosomes scale-up
- 19.2.1 Exosomes exhibit paracrine effects
- 19.2.2 Targeted delivery and precision medicine
- 19.2.3 Biocompatibility and immunomodulatory properties
- 19.2.4 Delivery system for blood brain barrier
- 19.2.5 Brain targeting and specificity
- 19.2.6 Neurological disorders and therapeutic applications
- 19.2.7 GMP compliant manufacturing methods of exosomes
- 19.2.8 isolation and purification of exosomes
- 19.2.9 Cell culture and supernatant collection
- 19.2.10 Centrifugation for debris removal
- 19.2.11 Ultracentrifugation for initial pelleting
- 19.2.12 Ultrafiltration for higher concentration
- 19.2.13 Size exclusion chromatography
- 19.2.14 Tangential flow filtration
- 19.2.14.1 Tangential flow filtration setup and operation
- 19.2.14.2 Collection of retentate and post-filtration processing
- 19.2.15 Quality Control and Quality Assurance of exosomes
- 19.2.16 Quantitative analysis
- 19.2.17 Purity assessment
- 19.2.18 Functional validation
- 19.2.19 Standardization and quality assurance
- 19.2.20 Regulatory compliance
- 19.2.21 Storage of exosomes
- 19.2.22 Temperature control
- 19.2.23 Avoidance of freeze-thaw cycles
- 19.2.24 Use of cryoprotectants
- 19.2.25 Lyophilization (freeze-drying)
- 19.2.26 Considerations for clinical applications
- 19.2.27 Optimization and validation
- 19.3 Conclusion
- 19.4 Future perspectives
- Chapter 20. Regulatory and ethical considerations in exosome-based therapeutics
- 20.1 Introduction
- 20.1.1 Overview of exosome-based therapeutics
- 20.1.2 Difficulties with treatments based on exosomes
- 20.1.3 Regulatory issues with exosome therapeutics
- 20.1.4 Importance of regulatory and ethical considerations
- 20.2 Key considerations for developing exosome-based therapeutics
- 20.3 Ethical challenges associated with exosome therapy
- 20.4 Current understanding in regulatory and ethical framework for exosome-based therapeutics
- 20.4.1 Regulatory landscape
- 20.4.1.1 Comparison with traditional pharmaceuticals and biologics
- 20.4.1.2 Existing guidelines and policies
- 20.4.2 Challenges in regulation
- 20.4.2.1 Standardization of isolation and characterization methods
- 20.4.2.2 Quality control and assurance
- 20.4.2.3 Reproducibility and scalability
- 20.4.3 Proposed regulatory pathways
- 20.4.3.1 Frameworks from leading regulatory bodies: FDA and EMA
- 20.4.3.2 Role of international collaboration and harmonization
- 20.5 GMP-grade exosome production methods
- 20.5.1 Purity, potency, and safety
- 20.5.2 Isolation
- 20.5.3 Standardization and characterization
- 20.5.4 Storage and stability
- 20.5.5 Clinical trials and dosing
- 20.5.6 Regulatory approval pathways
- 20.6 Exosome therapeutics: Preclinical and clinical considerations
- 20.6.1 Preclinical studies
- 20.6.2 Clinical trials
- 20.6.3 Dosing
- 20.6.4 Pharmacokinetics
- 20.6.5 Regulatory pathways
- 20.7 Regulatory and ethical issues in exosome therapeutics: Overcoming technical and biological obstacles
- 20.7.1 Challenges
- 20.7.2 Regulatory and ethical considerations
- 20.8 Discussion
- 20.9 Conclusion
- Index
- Edition: 1
- Published: November 15, 2024
- No. of pages (Paperback): 586
- No. of pages (eBook): 450
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780443290527
- eBook ISBN: 9780443290534
DG
Dalapathi Gugulothu
Dr. Dalapathi Gugulothu working as Assistant professor, Department of Pharmaceutics , Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University , New Delhi.
DK
Dharmendra Kumar Khatri
Dr. Dharmendra Kumar Khatri is an Associate Professor in the Department of Pharmacology, NIMS Institute of Pharmacy at NIMS University Rajasthan, Jaipur, India.
LV
Lalitkumar K. Vora
Dr. Lalitkumar K. Vora is a Lecturer at the School of Pharmacy, Queen’s University, Belfast, and was included in Stanford's top 2% of world scientists list in 2023.
WC
William C.S. Cho
Dr. William C. Cho, Highly Cited Researchers in 2023 by Clarivate. Dr. Cho has published over 600 SCI peer-reviewed papers; he is the world's top 0.1% most influential scientists in the world.